Updated on 13 November 2013
Mundipharma and Swiss subsidiary of Horizon Pharma sign exclusive agreement for commercialization and distribution of rheumatoid arthritis (RA) drug Lodotra in the Middle East and African region
Singapore: Mundipharma has signed an exclusive agreement with the Swiss subsidiary of Horizon Pharma for the commercialization and distribution of Lodotra in the Middle East and African region.
Lodotra, an innovative modified-release formulation of prednisone specifically designed to deliver the active drug at the most physiologically efficient time, is approved in the US (trade name Rayos) and over 30 other territories to treat moderate-to-severe active rheumatoid arthritis (RA), when accompanied by morning stiffness.
Mr Raman Singh, regional MD, Mundipharma Asia, Latin America, Middle East and Africa, said that, “We are excited to expand our collaboration with Horizon to new territories and offer a new therapeutic option for rheumatoid arthritis patients in the Middle East and Africa. Mundipharma has always focused on alleviating the burden of patients suffering from chronic pain. We are pleased to add Lodotra to our product portfolio as it represents an important advancement in improving the quality of life and outcomes for those afflicted with RA.”
Under the terms of the agreement, Mundipharma will have rights to commercialize Lodotra in 55 additional countries. Mundipharma will utilize a combination of company resources and partnerships to support the commercialization of the product in the new territories.
"Mundipharma has a highly respected reputation through its product portfolio across multiple geographies, including Lodotra in Europe, and we are pleased to expand our existing agreement with them to commercialize Lodotra in these additional territories," said Mr Todd N Smith, executive VP and chief commercial officer, Horizon Pharma.